Genmab A/S (NASDAQ:GMAB) Shares Gap Up – Still a Buy?

Genmab A/S (NASDAQ:GMAB)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $20.03, but opened at $20.76. Genmab A/S shares last traded at $20.71, with a volume of 171,097 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on GMAB shares. Redburn Atlantic began coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Wednesday, October 16th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a research note on Wednesday, September 11th. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Finally, Truist Financial cut their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Trading Up 3.3 %

The firm has a market cap of $13.69 billion, a PE ratio of 19.45, a PEG ratio of 0.67 and a beta of 0.96. The firm’s 50 day simple moving average is $22.01 and its 200 day simple moving average is $24.93.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million during the quarter, compared to analysts’ expectations of $838.20 million. During the same period last year, the company earned $0.47 earnings per share. As a group, equities research analysts predict that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Large investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its stake in Genmab A/S by 4.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 70,171 shares of the company’s stock valued at $1,763,000 after purchasing an additional 3,283 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Genmab A/S by 123.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock valued at $81,000 after buying an additional 1,787 shares in the last quarter. Crossmark Global Holdings Inc. increased its position in shares of Genmab A/S by 11.4% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 70,632 shares of the company’s stock worth $1,775,000 after purchasing an additional 7,242 shares in the last quarter. Ingalls & Snyder LLC lifted its position in shares of Genmab A/S by 29.3% during the second quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock worth $5,772,000 after purchasing an additional 52,117 shares in the last quarter. Finally, DDD Partners LLC acquired a new stake in shares of Genmab A/S during the second quarter worth $8,860,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.